New Weight-Loss Injection Helps Shed 14% Body Fat Within 28 Weeks In A Healthy Way – Faster Than Wegov
A new weight-loss injection has set a high standard for obesity patients, reducing their body weight by 14% in just 28 weeks, which is faster than the rate achieved with Wegovy. This Metsera-developed drug, MET-097i, is expanding obesity treatment options after the firm became part of Pfizer’s.
This experimental injection works 30% more efficiently than Wegovy. Its breakthrough performance in the early stages of use has garnered the attention of the NHS. The NHS has been exploring cost-effective and scalable solutions for patients with obesity for quite some time.
Clinical Trial Overview
In the first trial of MET-097i, 239 non-diabetic, obese adults were evaluated under the VESPER-1 Phase 2b study. They received a 1.2 mg injection once a week, and researchers monitored significant changes in body composition related to glucose control.
It was found that, within 28 weeks, the average weight loss was around 14.1%, which was surprising because the results were so consistent that no other drug could offer. However, the most astonishing part is that even some of the participants lost around 26.5% of their body fat in the same time duration.
Far beyond these shocking results, the researchers were turning heads when they observed that users continued to lose weight even after 36 weeks, a very rare phenomenon. It’s common for people to lose weight fast in the initial days of their weight loss journey.
However, once the water weight is shed, the body becomes more resistant to losing weight further, but this time, it was utterly surprising. The phase 2b drop rate was also relatively low, with only 2.9% quitting due to side effects.
Comparative Performance
The fat-shedding process of Wegovy is slower than that of MET-097i because Wegovy drops 15% fat in 68 weeks, as compared to MET-097i, which reduces 28% in just 28 weeks. Wegovy is a semaglutide, like Ozempic, like other drugs that come with side effects and a high bounce-back ratio.
Similarly, MET-097i is also stronger than the zepbound, a weight loss drug consisting of tirzepatide. Zepbund reduced its weight by around 20%, but it showed results in late-stage trials. However, MET-097i is relatively fast and promising in terms of weight loss.
The drug offers promising tolerability, meaning that all types of people, both those with a hard nature and those with a soft nature, benefit equally from the weight loss opportunity using this drug. Most importantly, both the side effects and dropout ratio are rare with MET-O97i.
Dr. John Buse calls the results of MET-097i “remarkable”. According to him, the drug has the potential to go viral as the only healthy weight loss treatment that is most effective and fastest. He also believes that this drug will exceed the user’s expectations and surpass all the other weight loss drugs available in the market.
Scientific Foundation
MET-097i works as a GLP-1 receptor agonist. It is derived from a gut protein library from Ziipp. It’s actually a nutrient-stimulated hormone analog that controls satiety and appetite related to all the hormones. It controls the entire digestion mechanism, from pre-processing to post-processing, including cravings and insulin sensitivity, in a strategic manner.
MET-097i’s safety and tolerability profile is quite high. It’s safe to use and commonly doesn’t have any side effects at all. But in rare cases only, it may induce nausea, diarrhea, and vomiting. According to the manufacturers, it is advised that the dose should be increased gradually rather than all at once.
Strategic and Market Implications
Pfizer put an upfront deal of $4.9 billion to acquire Mestera’s MET-097i. The company, once known as a giant in the healthcare industry, is now reentering the market with bigger names and greater impact.
The acquisition will not only present Pfizer as a giant in the industry, but also challenge the Zepbound and Wegovy in the international market. According to the NHS rollout under consideration, there is a high likelihood that the drug will be adopted in mainstream healthcare.
Regulatory and Next Steps
It is expected that in 2026, another trial of MET-097i will be conducted, referred to as a Phase 3 trial. Despite all the above specifications, the drug is still undergoing approval in many countries, including the United States, the United Kingdom, and several other European countries. What’s most important is that taking the drug once a month could improve access and adherence to the drug.
